LCMD-L302P-UCL01C2

General#

Cell Line

hPSCreg Name UCLi006-A
Alternative name(s)
LCMD-L302P-UCL01C2
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 13th March 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator University College London (UCL)
Distributors
Derivation country United Kingdom

External Databases

BioSamples SAMEA104130970
ECACC 66540593
Cellosaurus CVCL_VF11

General Information

Projects
Is the cell line available in principle? Available with restrictions: Available for commercial research

Donor Information#

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Congenital muscular dystrophy due to LMNA mutation (primary disease)
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • LMNA-related congenital muscular dystrophy
  • L-CMD
Genetic variants
LMNA (target)
1q21.1-21.2
c.905T>C
p.Leu302Pro
Heterozygous
18551513

External Databases (Donor)

BioSamples SAMEA104130971

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet: Jean-Marie.CUISSET@CHRU-LILLE.FR
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? Yes
Contact information / weblink
Alternatives to consent
Alternative consent approval number
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? Yes
Details on restriction to research project Use in research for muscular dystrophies
Does consent permit unforeseen future research, without further consent? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Policy for access to genetic information No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Please describe how access is provided:
Contact data, institution, or website:
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved?
Approval number
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved?
Approval number
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: Use in research for muscular dystrophies
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Further constraints on use
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Constraints for use or distribution

hIPSC Derivation#

General

Source cell type
fibroblast of dermis
Source cell origin
zone of skin
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
  • portion of skin
  • skin zone
  • region of skin
  • skin region
  • skin
show more synonyms

Reprogramming method

Vector type Integrating
Vector Virus (Lentivirus)
Genes
Is the used vector excisable?
No
Absence of reprogramming vector(s)?
No
Reprogramming vectors silenced?
Yes
Methods used
Immunostaining, RT-PCR
Vector map

Vector free reprogramming

Other

Derived under xeno-free conditions
Unkown
Derived under GMP?
Unkown
Available as clinical grade?
Unkown

Culture Conditions#

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
Medium TeSR™ E8™

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
NANOG
Yes
SOX2
Yes
POU5F1 (OCT-4)
Yes
Alkaline Phosphatase
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
Marker Expressed
Alpha FetoProtein
Yes
FOXA2
Yes
GATA Binding Protein 4
Yes
Mesoderm
Ont Id: UBERON_0000926
Marker Expressed
MSX1
Yes
Ectoderm
Ont Id: UBERON_0000924
Marker Expressed
MAP2
Yes
PAX6
Yes

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Normal
Karyotyping method: G-Banding

Other Genotyping (Cell Line)